Slide 1: Investor Presentation
5 March 2026 Steven Lydeamore Chief Executive Officer Investor Presentation NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended t
Slide 3: Immuron: integrated biopharmaceutical company focused on gut mediated diseases
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases Research & Development 2 pipeline assets to be partnered for development and commercialization Global footprint Au
Slide 4: Executive summary and 1H FY26 results
4 EBITDX (ex - R&D) 1 for HY26 was - A$1.1m, up A$0.1m on HY25 and up A$0.7m on 2H FY25 Cash of A$10.0 million, up A$7.2 million on 30 June 2025; equivalent to 22.5 months of cash used in operating activities in 1H FY26 R&D Tax Incentive A$1.1 million received in February 2026 1H FY 26 Results 1H FY
Slide 5: Immuron strategic reset provides clearer path to profitability
5 Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM - 124E and IMM - 529 for development and commercialization. • IMM - 124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s diarrhea
Slide 6: Traveler's Diarrhea market: TAM and SAM
TAM (Total Addressable Market) The global Traveler’s Diarrhea (TD) market, including all treatments (antibiotics, anti - diarrhea agents) and prevention (vaccines, probiotics). • Global Value : The global Traveler's Diarrhea treatment market is estimated at $3.31 billion for 2026, growing at a CAGR
Slide 7: C. difficile disease and market opportunity
The Disease: C. difficile is the leading cause of healthcare - associated infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild - to - moderate : Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PMC) : Colon wall plaques • Fulminant CDI
Slide 8: IMM deal potential and comparable transactions
8 IMM - 529 Deal Potential Status update (as of March 2026) Stage at deal Financial terms (public) Licensed Asset Licensee / Acquirer Licensor / Asset Owner Year FDA approved (Apr 2023) and commercialized by Nestlé Health Science; global rights consolidated under Nestlé via the 2024 transaction. ( U
Slide 9: Financial & Operational Highlights
1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 10: HY26 Financial Summary
10 HY26 Financial Summary Global Sales Revenue $4.2m Up 5% Australian Sales Revenue $3.3m Up 13% North American Sales Revenue $0.9m Down 1 18% USA Up 17% Gross Profit Margin 63% EBITDX (ex - R&D) 2 $(1.1)m Up $0.1m Up $0.7m on H2 FY25 4 Cash $10.0m Up $7.2m 3 on 30 Jun 25 ≈ 23.5 months cash (calcula
Slide 11: Continued strong sales growth
11 Continued strong sales growth Global + HY2026 AUD$4.2 million up 5% on prior year Australia + HY2026 AUD$3.3 million up 13% on prior year North America + HY2026 AUD$0.9 million down 18% on prior year + USA HY2026 AUD$0.9 million up 17% on prior year + Post HY, secured distribution with Jean Coutu
Slide 12: Commercial – Operational Highlights and Outlook
12 Commercial – Operational Highlights 2H FY24 1H FY25 2H FY25 1H FY26 and Outlook 1 Refer Travelan ® / Protectyn® • $4.18m global sales • $3.27m Australia • $0.91m North America • $3.29m global sales • $2.36m Australia • $0.93m North America • $3.99m global sales • $2.89m Australia • $1.11m North A
Slide 13: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: